


Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

4

Application Number	10/780,948
Filing Date	February 17, 2004
First Named Inventor	Erion et al.
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	45198.00016.DIV

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
PL		4,728,739		Kees et al.	03/01/88	
		4,791,125		Clark	12/13/88	
		4,968,790		De Vries et al.	11/06/90	
		5,236,941		Zask et al.	08/17/93	
		5,457,109		Antonucci et al.	10/10/95	
		5,468,762		Malamas et al.	11/21/95	
		5,478,853		Regnier et al.	12/26/95	
		5,532,256		Malamas et al.	07/02/96	
		5,658,889		Gruber et al.	08/19/97	
		6,028,052		Heyman et al.	02/22/00	
PL		6,200,998		Sahoo et al.	03/13/01	

FOREIGN PATENT DOCUMENTS							
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
PL		CA	2 173 660 A1		Kallam et al.	04/09/96	
		JP	07-002852 A2		Yoshioka et al.	01/06/95	
		EP	0 091 761 B1		Kawamatsu et al.	11/19/87	
		EP	0 129 747 A2		Hasler et al.	06/05/84	
		EP	0 177 353 A2		Meguro et al.	10/03/85	
		EP	0 283 035 A1		Iijima et al.	03/18/88	
		EP	0 427 799 B1		Gruber	01/24/90	
		EP	0 489 663 A1		Miyaoka et al.	12/06/91	
		EP	0 506 273 A2		Arita et al.	03/16/92	
		EP	0 543 662 A2		Fujita et al.	11/20/92	
PL		EP	0 559 571 A1		De nanteuil et al.	03/05/93	
		EP	0 708 098 A1		Yanagisawa et al.	10/09/95	
		EP	0 745 600 A1		Fujita et al.	12/04/96	
		EP	0 787 727 A1		Nagao et al.	08/06/97	

Examiner Signature

SAN /90564

Date

Considered


8-8-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/780,948
Filing Date	February 17, 2004
First Named Inventor	Erion et al.
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	45198.00016.DIV

PL	EP	0 861 666 A2		Ikeda et al.	09/02/98		
	WO	92/14719 A1		Ohnota et al.	09/03/92		
	WO	94/01433 A1		Shibata et al.	01/20/94		
	WO	95/026347 A1		Ohara et al.	10/05/95		
	WO	96/11196 A1		Ohara et al.	04/18/96		
	WO	96/26207 A1		Ohara et al.	08/29/96		
	WO	96/38427 A1		Yanagisawa et al.	12/05/96		
	WO	96/38428 A1		Maeda et al.	12/05/96		
	WO	96/39401 A1		Inman et al.	12/12/96		
	WO	97/10819		Heyman et al.	03/27/97		
	WO	97/37688 A2		Tamura et al.	10/16/97		
	WO	97/40051 A1		Takatani et al.	10/30/97		
	WO	98/39342 A1		Reddy et al.	09/11/98		
PL	WO	98/39343 A1		Kasibhatla et al.	09/11/98		
	WO	98/39344 A1		Dang et al.	09/11/98		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL		Amri et al., "Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene expression," <u>J. Lipid Res.</u> , 32:1449-1456 (1991).	
		Brown et al., "A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat," <u>Diabetes</u> , 48:1415-1424 (1999).	
		Clark et al., "Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents," <u>J. Med. Chem.</u> , 34:319-325 (1991).	
		Folli et al., "Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels," <u>J. Clin. Invest.</u> , 100(9):2158-2169 (1997).	
PL		Fujiwara et al., "Characterization of new oral antidiabetic agent CS-045: Studies in <i>KK</i> and <i>ob/ob</i> mice and Zucker fatty rats," <u>Diabetes</u> , 37:1549-1558 (1988).	

Examiner Signature

SAN /90564

Date Considered


8-8-06

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/780,948
		Filing Date	February 17, 2004
		First Named Inventor	Erion et al.
		Group Art Unit	1614
		Examiner Name	Not yet assigned
		Attorney Docket Number	45198.00016.DIV
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PL		Glucksmann et al., "novel mutations and a mutational hotspot in the MODY3 gene," <u>Diabetes</u> , 46:1081-1086 (1997).	
		Grimaldi et al., "Induction of a P2 gene expression by nonmetabolized long-chain fatty acids," <u>Proc. Natl. Sci. USA</u> , 89:10930-10934 (1992).	
		Howard et al., "Insulin sensitivity and atherosclerosis," <u>Circulation</u> , 93(10):1809-1817 (1996).	
		Hulin et al., "Novel thiazolidine-2,4-diones as potent euglycemic agents," <u>J. Med. Chem.</u> , 35:1853-1864 (1992).	
		Lehmann et al., "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)," <u>J. Biol. Chem.</u> , 270(22):12953-6 (1995).	
		Maryanoff et al., "Stereoselective synthesis and biological activity of β - and α -D-arabinose 1,5-diphosphate: Analogues of a potent metabolic regulator," <u>J. Am. Chem. Soc.</u> , 106:7851-7853 (1984).	
		Mathisen et al., "The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes," <u>Diabetes</u> , 48(Suppl. 1):0441 (1998).	
		Patel et al. "Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study," <u>Diabetes, Obesity and Metabolism</u> , 1:165-172 (1999).	
		Riddle, "New tactics for type 2 diabetes: Regimens based on intermediate-acting insulin taken at bedtime," <u>The Lancet</u> , 192-195 (1985).	
		Saltiel & Olefsky, "Thiazolidinediones in the treatment of insulin resistance and type II diabetes," <u>Diabetes</u> , 45:1661-1669 (1996).	
		Scheen et al., "Oral antidiabetic agents: A guide to selection," <u>Drugs</u> , 55:225-236 (1998).	
V		Schmitz-Peiffer et al., "Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653," <u>Am. J. Physiol.</u> , 273:E915-E921 (1997).	
PL		Sreenan et al., "Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone," <u>Am. J. Physiol.</u> , 271:E742-747 (1996).	


Examiner Signature	SAN /905644 	Date Considered	8-8-06
--------------------	-----------------	-----------------	--------

¹ EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/780,948
		Filing Date	February 17, 2004
		First Named Inventor	Erion et al.
		Group Art Unit	1614
		Examiner Name	Not yet assigned
		Attorney Docket Number	45198.00016.DIV
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
fl		Tontonoz et al., "Stimulation of Adipogenesis in fibroblasts by PPARY2, a lipid-activated transcription factor," <u>Cell</u> , 79:1147-1159 (1994).	
		Tontonoz et al., "mPPAR γ 2: Tissue specific regulator of an adipocyte enhancer," <u>Gene and Development</u> , 8:1224-1234 (1994).	
		Torlone et al., "Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes," <u>Diabetes Care</u> , 16(10):1347-1355 (1993).	
		U.K. prospective diabetes study group, "U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease," <u>Diabetes</u> , 44:1249-1258 (1995).	
		Valiquett et al., "Troglitazone dose-response study in patients with NIDDM," <u>Diabetes</u> , 44(Suppl. 1):406 (1995).	
		Willson et al., "The structure-activity relationship between peroxisome proliferators-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones," <u>J. Med. Chem.</u> , 39:665-668 (1996).	
		Zask et al., "Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2, 4-thiazolidinediones," <u>J. Med. Chem.</u> , 33:1418-1423 (1990).	
		<u>Diabetologia</u> , 36 (Suppl.):182A (1993).	
V		<u>Diabetes</u> , 42 (Suppl.):79A (1993).	
fl		<u>Diabetes</u> , 45 (Suppl. 2):141A (1996).	

Examiner Signature	SAN /90564.1 	Date Considered	8-8-05
--------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.